2/25
09:39 am
krys
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
2/24
08:00 am
krys
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Low
Report
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
2/24
04:32 am
krys
Krystal Biotech's KB707 RMAT Win Opens New Lung Cancer Chapter [Yahoo! Finance]
Medium
Report
Krystal Biotech's KB707 RMAT Win Opens New Lung Cancer Chapter [Yahoo! Finance]
2/22
01:22 pm
krys
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 [Yahoo! Finance]
Medium
Report
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 [Yahoo! Finance]
2/21
06:44 am
krys
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating [Yahoo! Finance]
Medium
Report
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating [Yahoo! Finance]
2/19
06:47 pm
krys
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/18
08:13 am
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
2/18
07:18 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/17
04:21 pm
krys
Krystal Biotech Inc (KRYS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Krystal Biotech Inc (KRYS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/17
04:01 pm
krys
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/17
03:56 pm
krys
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook [Seeking Alpha]
Low
Report
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook [Seeking Alpha]
2/17
03:11 pm
krys
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology [Seeking Alpha]
Low
Report
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology [Seeking Alpha]
2/17
02:05 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
2/17
12:46 pm
krys
Krystal Biotech, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Krystal Biotech, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/17
11:01 am
krys
Krystal Biotech Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Krystal Biotech Q4 Earnings Call Highlights [Yahoo! Finance]
2/17
07:00 am
krys
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Medium
Report
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
2/17
02:38 am
krys
Assessing Krystal Biotech (KRYS) Valuation After RMAT Designation For KB707 Immunotherapy Candidate [Yahoo! Finance]
Medium
Report
Assessing Krystal Biotech (KRYS) Valuation After RMAT Designation For KB707 Immunotherapy Candidate [Yahoo! Finance]
2/16
04:35 pm
krys
What Krystal Biotech (KRYS)'s RMAT Status for KB707 Means For Shareholders [Yahoo! Finance]
Medium
Report
What Krystal Biotech (KRYS)'s RMAT Status for KB707 Means For Shareholders [Yahoo! Finance]
2/10
01:46 pm
krys
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]
Low
Report
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]
2/10
08:00 am
krys
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Low
Report
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
2/9
08:00 am
krys
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Low
Report
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
2/7
06:18 am
krys
Krystal Biotech (NASDAQ:KRYS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Krystal Biotech (NASDAQ:KRYS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/3
09:06 pm
krys
Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]
Medium
Report
Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]
1/30
08:14 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/22
01:21 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.